Drug intelligence / Profile preview

Bifidobacterium animalis subsp. lactis BAu-B111

Development stage: Preclinical
Lead developer: The Second Affiliated Hospital of Nanchang University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium animalis subsp. lactis BAu-B111 is a specific probiotic strain of the Bifidobacterium genus. It is being investigated as a live biotherapeutic product for the treatment of functional constipation in patients with Parkinson's disease. The strain is often evaluated in combination with traditional Chinese medicine, such as the Liuweianxiao capsule, to modulate the gut microbiota and improve gastrointestinal motility. Probiotics like BAu-B111 are thought to exert their effects by restoring microbial balance, producing short-chain fatty acids, and potentially influencing the gut-brain axis, which is increasingly recognized as a factor in Parkinson's disease progression and symptoms.

Targets

TLR9 (Toll-like receptor 9)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on Bifidobacterium animalis subsp. lactis BAu-B111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium animalis subsp. lactis BAu-B111.

Explore the full profile